Metrics as of 10/17/2026, 08:35 AM (Berlin time), refresh in progress.
Shield Therapeutics Stock
Shield Therapeutics plc
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United Kingdom
- CEO
- Anders Lundstrom
- Employees
- 61
- Market cap
- £56 M
- IPO
- 26/02/2016
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia.…
Shield Therapeutics stock: price history
1D
+0.0%
1W
-1.9%
1M
+14.3%
6M
-44.4%
YTD
-47.2%
1Y
-33.8%
2Y
+14.3%
5Y
-86.3%
10Y
-97.0%
Next earnings date
Next earnings date
29/04/2027 (in 194 days)
Volatility around earnings
~48% stronger price swings than usual
Ask the agents about Shield Therapeutics
Shield Therapeutics stock metrics
P/E
-7.07
P/B
-4.33
EV/EBITDA
-28.26
RETURN ON EQUITY
13.1%
NET MARGIN
-7.4%
DEBT/EQUITY
-1.46
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
38.2%
FLOAT SHARES
410,782,416
AVG. DAILY VOLUME (30D)
1,937,337
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Shield Therapeutics stock
What does Shield Therapeutics do?
Shield Therapeutics plc is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United Kingdom.
The CEO is Anders Lundstrom, the company employs around 61 people.
The IPO was on 26/02/2016; the stock trades on LSE under the ticker STX.L.
When does Shield Therapeutics report next?
The next earnings date is 29/04/2027.
Around past earnings, price swings were roughly 48% stronger than usual.
Does Shield Therapeutics pay a dividend?
No, Shield Therapeutics currently does not pay a dividend.
Which stocks are comparable to Shield Therapeutics?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Shield Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Shield Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.